usistapide
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00622765)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Methionine aminopeptidase 2INHIBITOR
METAP2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)[C@H](c1ccccc1)N1CCC(c2ccc(NC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)cc2)CC1- Mol. weight
- 572.63 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103860 ↗
Also known as
- jnj16269110
- jnj-16269110
- jnj-16269110
- r256918
- r256918
- r-256918
- r-256918
- usistapide
- usistapide
- usistapide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01041677 | Phase 2 | Feb 1, 2008 | Johnson and Johnson |
| NCT00672386 | Phase 2 | Dec 1, 2007 | Johnson and Johnson |
| NCT00622765 | Phase 2 | Nov 1, 2007 | Johnson and Johnson |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 3 | 3 | 1 | 2007 |
1 organizations
Page 1 / 1